(Q30244553)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27743148%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

review article

1 reference

title

T-cell lymphomas, a challenging disease: types, treatments, and future (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27743148%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27743148%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

author name string

Helen Ma

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27743148%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

publication date

14 October 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27743148%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Clinical Oncology

25 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27743148%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27743148%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27743148%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

page(s)

18-51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27743148%20AND%20SRC:MED&resulttype=core&format=json

Discovery of adult T-cell leukemia

25 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Molecular Pathology of Adult T-Cell Leukemia/Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Age- and sex-specific cumulative rate and risk of ATLL for HTLV-I carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Increase in incidence of adult T-cell leukemia/lymphoma in non-endemic areas of Japan and the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Integrated molecular analysis of adult T cell leukemia/lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Variegated RHOA mutations in adult T-cell leukemia/lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Therapeutic options for adult T-cell leukemia/lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Treatment and survival among 1594 patients with ATL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Small number of HTLV-1-positive cells frequently remains during complete remission after allogeneic hematopoietic stem cell transplantation that are heterogeneous in origin among cases with adult T-cell leukemia/lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Small PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Angioimmunoblastic T-cell lymphoma: a diagnostic challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Evaluation of cutaneous angioimmunoblastic T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Angioimmunoblastic T-cell lymphoma with autoimmune thrombocytopenia: a report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Epstein-Barr virus in angioimmunoblastic T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

T- and B-cell clonality and frequency of human herpes viruses-6, -8 and Epstein Barr virus in angioimmunoblastic T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Angioimmunoblastic lymphadenopathy with dysproteinemia: emphasis on pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Angioimmunoblastic T-cell Lymphomas With the RHOA p.Gly17Val Mutation Have Classic Clinical and Pathologic Features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

IL-21-driven neoplasms in SJL mice mimic some key features of human angioimmunoblastic T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Pathobiology of T-cell and NK-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Pralatrexate pharmacology and clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Large cell anaplastic lymphoma (Ki-1 lymphoma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Twelve cases of Ki-1 positive anaplastic large cell lymphoma of skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

CD30 expression in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Antibody BNH9 detects red blood cell-related antigens on anaplastic large cell (CD30+) lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Variable expression of leucocyte-common (CD45) antigen in CD30 (Ki1)-positive anaplastic large-cell lymphoma: implications for the differential diagnosis between lymphoid and nonlymphoid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Genotypic analysis in large cell lymphomas expressing a restricted set of differentiation antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ('Ki-1 lymphoma').

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Molecular Pathogenesis of Peripheral T Cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Anaplastic large-cell lymphoma in women with breast implants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Silicone implants and lymphoma: The role of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Tumor viruses in CD30-positive anaplastic large cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Crizotinib in anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

CD56 (NKH1)-positive hematolymphoid malignancies: an aggressive neoplasm featuring frequent cutaneous/mucosal involvement, cytoplasmic azurophilic granules, and angiocentricity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Epstein-Barr virus-associated natural killer/T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Nasal and nasal-type T/NK cell lymphoma: a unique form of lymphoma associated with the Epstein-Barr virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

ATP-binding cassette sub-family C member 4 (ABCC4) is overexpressed in human NK/T-cell lymphoma and regulates chemotherapy sensitivity: Potential as a functional therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Bortezomib for the treatment of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Cutaneous T-Cell Lymphomas: The Sézary Syndrome, Mycosis Fungoides, and Related Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Alibert lymphoma: renaming mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Mycosis fungoides: clinical and histologic features, staging, evaluation, and approach to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Identification of Subpopulations of Mononuclear Cells in Cutaneous Infiltrates I. Differentiation Between B Cells, T Cells, and Histiocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Tumor microenvironment in mycosis fungoides and Sézary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Mac attack: macrophages as key drivers of cutaneous T-cell lymphoma pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Infectious agents in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Black cat in a dark room: the absence of a directly oncogenic virus does not eliminate the role of an infectious agent in cutaneous T-cell lymphoma pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Mycosis fungoides and Sezary syndrome are not associated with HTLV-I infection: an international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Hydrochlorothiazide and cutaneous T cell lymphoma: prospective analysis and case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Development of all CD4 T lineages requires nuclear factor TOX

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6, in advanced cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

CD30 expression and proliferative fraction in nontransformed mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

WHO-EORTC classification for cutaneous lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Topical corticosteroids for mycosis fungoides. Experience in 79 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Treatment of patch-stage mycosis fungoides with topical corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Total Skin Electron Beam for Primary Cutaneous T-cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Revisiting low-dose total skin electron beam therapy in mycosis fungoides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Optimizing bexarotene therapy for cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Interferon in the treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

The treatment of cutaneous T-cell lymphoma with photopheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Mogamulizumab benefits seen in cutaneous T-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Meta-Analysis on the Use of Zidovudine and Interferon-Alfa in Adult T-Cell Leukemia/Lymphoma Showing Improved Survival in the Leukemic Subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-016-1045-2

Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation)

21 January 2018

1 reference

12 December 2020

Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers.

1 reference

12 December 2020

Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma

1 reference

12 December 2020

Anaplastic large cell lymphoma, CD30/Ki-1 positive, expressing the CD15/Leu-M1 antigen. Immunohistochemical and morphological relationships to Hodgkin's disease

1 reference

12 December 2020

Rearrangement of the T-cell receptor delta chain gene in T-cell lymphomas with a mature phenotype

1 reference

12 December 2020

Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience

1 reference

12 December 2020

CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features

1 reference

12 December 2020

Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity.

1 reference

12 December 2020

Adult Ki-1-positive large cell anaplastic lymphoma presenting with skin lesions

1 reference

12 December 2020

First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma

1 reference

12 December 2020

CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance

1 reference

12 December 2020

Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study

1 reference

12 December 2020

Angio-immunoblastic lymphadenopathy with dysproteinaemia

1 reference

12 December 2020

Adult T-cell leukaemia and lymphoma: report of two cases and a brief review of the literature.

1 reference

12 December 2020

The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements

1 reference

12 December 2020

CD56+ NK lymphomas: clinicopathological features and prognosis

1 reference

12 December 2020

Anaplastic large cell Ki-1 lymphoma. Delineation of two morphological types

1 reference

12 December 2020

Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome

1 reference

12 December 2020

Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II

1 reference

12 December 2020

Pleomorphic T-cell lymphoma and large-cell anaplastic lymphoma of the skin. A morphological, immunophenotypical, and ultrastructural study of two typical cases

1 reference

12 December 2020

Mogamulizumab: 2 birds, 1 stone

1 reference

12 December 2020

Ki-1+ anaplastic large-cell lymphoma of T-cell origin in an HIV-infected patient

1 reference

12 December 2020

Hodgkin's disease and CD30-positive anaplastic large cell lymphomas--a continuous spectrum of malignant disorders. A quantitative morphometric and immunohistologic study

1 reference

12 December 2020

Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1

1 reference

12 December 2020

Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation.

1 reference

12 December 2020

Primary Ki-1 (CD 30)-positive, large cell, anaplastic lymphoma of the esophagus

1 reference

12 December 2020

Expression of the novel intermediate filament-associated protein restin in Hodgkin's disease and anaplastic large-cell lymphoma

1 reference

12 December 2020

Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study

1 reference

12 December 2020

Role of beta 1-integrins in epidermotropism of malignant T cells.

1 reference

12 December 2020

Clinicopathologic, immunophenotypic, and immunogenotypic analyses of immunoblastic lymphadenopathy-like T-cell lymphoma

1 reference

12 December 2020

Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease

1 reference

12 December 2020

Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma

1 reference

12 December 2020

Adult T-cell leukemia: clinical and hematologic features of 16 cases

1 reference

12 December 2020

Clinicopathologic study of large cell anaplastic lymphoma (Ki-1-positive large cell lymphoma) among the Japanese

1 reference

12 December 2020

Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load

1 reference

12 December 2020

The development of a Ki-1-positive large cell non-Hodgkin's lymphoma in pagetoid reticulosis

1 reference

12 December 2020

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study

1 reference

12 December 2020

Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma

1 reference

12 December 2020

Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion

1 reference

12 December 2020

Angioimmunoblastic t-cell lymphoma presenting as purpura fulminans

1 reference

12 December 2020

Angioimmunoblastic T-cell lymphoma (AIL-TCL) following macrolide administration

1 reference

12 December 2020

Genotypic and immunophenotypic analysis of anaplastic large cell lymphoma (Ki-1 lymphoma)

1 reference

12 December 2020

Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients

1 reference

12 December 2020

Primary and secondary cutaneous Ki-1+ (CD30+) anaplastic large cell lymphomas. Morphologic, immunohistologic, and clinical-characteristics

1 reference

12 December 2020

Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome

1 reference

12 December 2020

Superantigenic exotoxin-secreting potential of staphylococci isolated from atopic eczematous skin

1 reference

12 December 2020

Natural killer cell lymphoma/leukemia: pathology and treatment

1 reference

12 December 2020

Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy

1 reference

12 December 2020

Discordant intracellular and plasma D-2-hydroxyglutarate levels in a patient with IDH2 mutated angioimmunoblastic T-cell lymphoma

1 reference

12 December 2020

Paraffin section immunohistochemistry. II. Hodgkin's disease and large cell anaplastic (Ki1) lymphoma

1 reference

12 December 2020

Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma

1 reference

12 December 2020

Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sézary syndrome

1 reference

12 December 2020

Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma

1 reference

12 December 2020

[Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen]

1 reference

12 December 2020

Dysregulation of microRNAs in angioimmunoblastic T-cell lymphoma

1 reference

12 December 2020

Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant

1 reference

12 December 2020

Cytokeratin expression and vimentin content in large cell anaplastic lymphomas and other non-Hodgkin's lymphomas

1 reference

12 December 2020

Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis

1 reference

12 December 2020

Aggressive natural killer cell leukemia/lymphoma with N901-positive surface phenotype: evidence for the existence of a third lineage in lymphoid cells.

1 reference

12 December 2020

Ki-1-positive large-cell anaplastic lymphoma with protean manifestations including central nervous system involvement

1 reference

12 December 2020

Efficacy and safety evaluation of gemcitabine combined with oxaliplatin in lymphoma patients after failure of multiple chemotherapy regimens

1 reference

12 December 2020

Primary intestinal lymphoma of Ki-1 large cell anaplastic type with mesenteric lymph node and spleen involvement in a renal transplant recipient

1 reference

12 December 2020

Detection of Epstein-Barr virus genome in Ki-1 (CD30)-positive, large-cell anaplastic lymphomas using the polymerase chain reaction

1 reference

12 December 2020

Primary cerebral anaplastic T-cell-lymphoma (type Ki-1): review and case report

1 reference

12 December 2020

The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma.

1 reference

12 December 2020

Narrowband UVB phototherapy for early-stage mycosis fungoides

1 reference

12 December 2020

Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma

1 reference

12 December 2020

Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution

1 reference

12 December 2020

Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified

1 reference

12 December 2020

Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma

1 reference

12 December 2020

Human T-cell leukemia virus type I induces adult T-cell leukemia: from clinical aspects to molecular mechanisms

1 reference

12 December 2020

Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome

1 reference

12 December 2020

Histopathologic, immunophenotypic, and genotypic analysis of Ki-1 anaplastic large cell lymphomas that express histiocyte-associated antigens

1 reference

12 December 2020

How I treat NK/T-cell lymphomas

1 reference

12 December 2020

Study on activation of AKT/mTOR pathway in anaplastic large cell lymphoma

1 reference

12 December 2020

The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells

1 reference

12 December 2020

Ultrastructural comparison of human platelets separated from blood by various means

1 reference

12 December 2020

Classification of natural killer (NK) cell and NK-like T-cell malignancies

1 reference

12 December 2020

IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases

1 reference

12 December 2020

Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).

1 reference

12 December 2020

Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma

1 reference

12 December 2020

Expanding the portfolio of anti-ALK weapons

1 reference

12 December 2020

Angioimmunoblastic T-cell lymphoma

1 reference

12 December 2020

Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL)

1 reference

12 December 2020

Interferon alfa-2a in the treatment of cutaneous T cell lymphoma

1 reference

12 December 2020

Drug-induced reversible lymphoid dyscrasia: a clonal lymphomatoid dermatitis of memory and activated T cells

1 reference

12 December 2020

BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope

1 reference

12 December 2020

Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation

1 reference

12 December 2020

Extranodal Ki-1 lymphoma in a renal transplant patient

1 reference

12 December 2020

Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation

1 reference

12 December 2020

Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma

1 reference

12 December 2020

Mycosis fungoides--a disease of antigen persistence

1 reference

12 December 2020

Phase 2 trial of "sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma

1 reference

12 December 2020

CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas

1 reference

12 December 2020

Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (Mycosis Fungoides)

1 reference

12 December 2020

Anaplastic large cell lymphoma (Ki-1+/CD30+) in childhood

1 reference

12 December 2020

Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma

1 reference

12 December 2020

FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome

1 reference

12 December 2020

Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study. Lymphoma Study Group (1984-1987)

1 reference

12 December 2020

Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity

1 reference

12 December 2020

Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides

1 reference

12 December 2020

Ki-1-positive large cell lymphomas, a heterogenous group of neoplasms. Morphologic, immunophenotypic, genotypic, and clinical features of 24 cases

1 reference

12 December 2020

Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.

1 reference

12 December 2020

10.1007/S10147-016-1045-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27743148%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1 reference